Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET
Company Participants
Sasha Ellis - VP, Corporate Affairs & IR
Scott Braunstein - CEO, President & Director
Christy Shafer - Chief Commercial Officer
Joseph Hulihan - Chief Medical Officer
Steven Pfanstiel - CFO & Treasurer
Conference Call Participants
Andrew Tsai - Jefferies
Charles Duncan - Cantor Fitzgerald & Co.
Douglas Tsao - H.C. Wainwright & Co.
Jay Olson - Oppenheimer
Michael Higgins - Ladenburg Thalmann & Co.
Brian Skorney - Robert W. Baird & Co.
Marc Goodman - SVB Securities
Joon Lee - Truist Securities
Jason Butler - JMP Securities
Joseph Thome - Cowen and Company
Operator
Greetings and welcome to the Marinus Pharmaceuticals Second Quarter 2022 Financial Results and Business Update Call. This time all participants are in listen-only mode. After the speakers' presentation there will be a question-and-answer session.
Now it is my pleasure to introduce your host, Sasha Ellis, Vice President of Corporate Affairs and Investor Relations. You may begin Ms. Damouni Ellis.
Sasha Ellis
Thank you and good morning. With me from Marinus are Dr. Scott Braunstein, Chief Executive Officer; Christy Shafer, Chief Commercial Officer; Dr. Joe Hulihan, Chief Medical Officer; and Steve Pfanstiel, Chief Financial Officer. Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws.
These forward looking statements and both substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Form 10-K, 10-Q and 8-K.
I'll now turn the call over to our CEO, Scott Braunstein.
Scott Braunstein
Thank you Sasha and welcome to our call. We ended the first quarter with the exciting news that ZTALMY received FDA approval for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. And pleased to now be receiving our first prescription and completed patient enrolment forms.
Our sales force has been in the field engaging and educating physicians as CDD centers of excellence and National Epilepsy Centers. We are encouraged by the strong early interest in the ZTALMY. In addition to the April publication of the Phase III Marigold results in the Lancet Neurology. First international consensus recommendation for the assessment and management of individuals with CDKL5 deficiency disorder was published in Frontiers in Neurology in June.